Polaryx Therapeutics (PLYX) Stock Analysis

What Polaryx Therapeutics does

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.

Key metrics

ETFs linked to PLYX

Broad-market and Healthcare sector ETFs an investor holding Polaryx Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PLYX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Polaryx Therapeutics?

Polaryx Therapeutics trades under the ticker PLYX on NASDAQ.

Which exchange is PLYX listed on?

PLYX is listed on NASDAQ.

What sector does Polaryx Therapeutics operate in?

Polaryx Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PLYX in a portfolio?

PortView shows PLYX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.